Cooperative Agreement R44CA195793

This $999,960 Project Grant award from the National Cancer Institute's (CFDA 93.395) Cancer Treatment Research program supports the development of LNS8801, a small molecule therapeutic for cutaneous melanoma patients who cannot tolerate immunotherapy. The funding will enable Linnaeus Therapeutics Inc. to advance LNS8801 through human clinical trials, building on preclinical work that has demonstrated LNS8801's antitumor efficacy and safety profile. LNS8801 is an orally deliverable, small...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded $727,732 to Sloan-Kettering Institute for Cancer Research on June 3, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct clinical and translational research aimed at improving CDK4/6 inhibitor (CDK4/6I) therapy for patients with dedifferentiated liposarcoma (DDLS). The primary deliverable is a Phase IB/II clinical trial rich in correlative science to evaluate the efficacy of palbociclib in...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $716,521 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on August 25, 2025, with a completion date of July 31, 2030. This grant funds the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cell therapy for treating small cell lung cancer (SCLC), a disease with exceptionally poor prognosis and limited...

Federal Project Grant Award Summary Columbia University's Health Sciences Division, in receipt of a $109,080 Project Grant awarded September 1, 2025, by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), is conducting a Phase II investigator-initiated, multicenter randomized controlled trial (RCT) evaluating a novel immunotherapeutic approach for treatment-naive metastatic pancreatic adenocarcinoma (MPDA). The trial compares a four-drug regimen...

Grant Award Summary Cryocrate LLC received a $292,963 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 17, 2025, with completion targeted for August 31, 2028. The company is developing Odinsol, a novel polysaccharide-based cryopreservation medium designed to preserve natural killer (NK) cells for cancer immunotherapy applications. Unlike current cryopreservation methods that use toxic, cell-permeating cryoprotectants,...

Federal Grant Award Summary Glycyx Mor, Inc. received a $1.197 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 19, 2025, with completion targeted for August 31, 2027. The grant supports a Phase 2 clinical trial evaluating axelopran, a peripherally-restricted opioid antagonist, as an adjunctive therapy to pembrolizumab for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $433,157 to the Northshore University Healthsystem Research Institute to investigate the role of lipid-rich macrophages in the tumor microenvironment of prostate cancer. The primary objectives are to define the mechanisms regulating the immuno-metabolic axis in adipose tissue macrophages and tumor-associated macrophages, and determine whether a metabolically-activated macrophage...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund a 5-year, $706,669 multi-site, triple-blind, placebo-controlled, Phase II randomized clinical trial to investigate the effects of photobiomodulation therapy (PBMT) on chronic lymphedema in head and neck cancer survivors. The principal goal is to evaluate the efficacy of PBMT for reducing the severity of external and internal lymphedema, as well as its impact on symptom burden and...

Federal Grant Award Summary Neonc Technologies Inc. received a $399,998 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 7, 2025, with completion targeted for July 31, 2026. The grant funds preclinical development and regulatory preparation activities for NEO212, a novel oral small molecule therapeutic candidate designed to treat acute myeloid leukemia (AML). NEO212 is a covalent conjugate of perillyl alcohol and...